These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

500 related articles for article (PubMed ID: 32615108)

  • 1. Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial.
    Heinrich MC; Jones RL; von Mehren M; Schöffski P; Serrano C; Kang YK; Cassier PA; Mir O; Eskens F; Tap WD; Rutkowski P; Chawla SP; Trent J; Tugnait M; Evans EK; Lauz T; Zhou T; Roche M; Wolf BB; Bauer S; George S
    Lancet Oncol; 2020 Jul; 21(7):935-946. PubMed ID: 32615108
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Avapritinib in unresectable or metastatic PDGFRA D842V-mutant gastrointestinal stromal tumours: Long-term efficacy and safety data from the NAVIGATOR phase I trial.
    Jones RL; Serrano C; von Mehren M; George S; Heinrich MC; Kang YK; Schöffski P; Cassier PA; Mir O; Chawla SP; Eskens FALM; Rutkowski P; Tap WD; Zhou T; Roche M; Bauer S
    Eur J Cancer; 2021 Mar; 145():132-142. PubMed ID: 33465704
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical efficacy comparison of avapritinib with other tyrosine kinase inhibitors in gastrointestinal stromal tumors with PDGFRA D842V mutation: a retrospective analysis of clinical trial and real-world data.
    von Mehren M; Heinrich MC; Shi H; Iannazzo S; Mankoski R; Dimitrijević S; Hoehn G; Chiroli S; George S
    BMC Cancer; 2021 Mar; 21(1):291. PubMed ID: 33740926
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III Study.
    Kang YK; George S; Jones RL; Rutkowski P; Shen L; Mir O; Patel S; Zhou Y; von Mehren M; Hohenberger P; Villalobos V; Brahmi M; Tap WD; Trent J; Pantaleo MA; Schöffski P; He K; Hew P; Newberry K; Roche M; Heinrich MC; Bauer S
    J Clin Oncol; 2021 Oct; 39(28):3128-3139. PubMed ID: 34343033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Avapritinib in the treatment of PDGFRA exon 18 mutated gastrointestinal stromal tumors.
    Smrke A; Gennatas S; Huang P; Jones RL
    Future Oncol; 2020 Aug; 16(22):1639-1646. PubMed ID: 32517495
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Avapritinib in Patients With Advanced Gastrointestinal Stromal Tumors Following at Least Three Prior Lines of Therapy.
    George S; Jones RL; Bauer S; Kang YK; Schöffski P; Eskens F; Mir O; Cassier PA; Serrano C; Tap WD; Trent J; Rutkowski P; Patel S; Chawla SP; Meiri E; Gordon M; Zhou T; Roche M; Heinrich MC; von Mehren M
    Oncologist; 2021 Apr; 26(4):e639-e649. PubMed ID: 33453089
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of Avapritinib in Treating Unresectable or Metastatic Gastrointestinal Stromal Tumors: A Phase I/II, Open-Label, Multicenter Study.
    Li J; Zhang X; Deng Y; Wu X; Zheng Z; Zhou Y; Cai S; Zhang Y; Zhang J; Tao K; Cui Y; Cao H; Shen K; Yu J; Zhou Y; Ren W; Qu C; Zhao W; Hu J; Wang W; Yang J; Shen L
    Oncologist; 2023 Feb; 28(2):187-e114. PubMed ID: 36477870
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The EMA assessment of avapritinib in the treatment of gastrointestinal stromal tumours harbouring the PDGFRA D842V mutation.
    Trullas-Jimeno A; Delgado J; Garcia-Ochoa B; Wang I; Sancho-Lopez A; Payares-Herrera C; Dalhus ML; Strøm BO; Egeland EJ; Enzmann H; Pignatti F
    ESMO Open; 2021 Jun; 6(3):100159. PubMed ID: 34023541
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimal Avapritinib Treatment Strategies for Patients with Metastatic or Unresectable Gastrointestinal Stromal Tumors.
    Joseph CP; Abaricia SN; Angelis MA; Polson K; Jones RL; Kang YK; Riedel RF; Schöffski P; Serrano C; Trent J; Tetzlaff ED; Si TD; Zhou T; Doyle A; Bauer S; Roche M; Havnaer T
    Oncologist; 2021 Apr; 26(4):e622-e631. PubMed ID: 33301227
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Financial Implications of Avapritinib for Treatment of Unresectable Gastrointestinal Stromal Tumors in Patients With a PDGFRA Exon 18 Variant or After 3 Previous Therapies in a Hypothetical US Health Plan.
    Proudman D; Miller A; Nellesen D; Gomes A; Mankoski R; Norregaard C; Sullivan E
    JAMA Netw Open; 2020 Nov; 3(11):e2025866. PubMed ID: 33201235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial.
    Blay JY; Serrano C; Heinrich MC; Zalcberg J; Bauer S; Gelderblom H; Schöffski P; Jones RL; Attia S; D'Amato G; Chi P; Reichardt P; Meade J; Shi K; Ruiz-Soto R; George S; von Mehren M
    Lancet Oncol; 2020 Jul; 21(7):923-934. PubMed ID: 32511981
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinicopathological features and prognosis of gastrointestinal stromal tumor with PDGFRA-D842V mutation].
    Li XQ; Tu L; Wang M; Ma XL; Yang LX; Shen YY; Zhuang C; Zhao WY; Qiu JF; Zhao G; Cao H
    Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Sep; 23(9):872-879. PubMed ID: 32927512
    [No Abstract]   [Full Text] [Related]  

  • 13. Avapritinib in unresectable or metastatic gastrointestinal stromal tumor with PDGFRA exon 18 mutation: safety and efficacy.
    Henriques-Abreu M; Serrano C
    Expert Rev Anticancer Ther; 2021 Oct; 21(10):1081-1088. PubMed ID: 34404327
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Avapritinib: First Approval.
    Dhillon S
    Drugs; 2020 Mar; 80(4):433-439. PubMed ID: 32100250
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study.
    Lakhani NJ; Chow LQM; Gainor JF; LoRusso P; Lee KW; Chung HC; Lee J; Bang YJ; Hodi FS; Kim WS; Santana-Davila R; Fanning P; Squifflet P; Jin F; Kuo TC; Wan HI; Pons J; Randolph SS; Messersmith WA
    Lancet Oncol; 2021 Dec; 22(12):1740-1751. PubMed ID: 34793719
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resistance to Avapritinib in PDGFRA-Driven GIST Is Caused by Secondary Mutations in the PDGFRA Kinase Domain.
    Grunewald S; Klug LR; Mühlenberg T; Lategahn J; Falkenhorst J; Town A; Ehrt C; Wardelmann E; Hartmann W; Schildhaus HU; Treckmann J; Fletcher JA; Jung S; Czodrowski P; Miller S; Schmidt-Kittler O; Rauh D; Heinrich MC; Bauer S
    Cancer Discov; 2021 Jan; 11(1):108-125. PubMed ID: 32972961
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical characteristics and treatment outcome in a large multicentre observational cohort of PDGFRA exon 18 mutated gastrointestinal stromal tumour patients.
    Farag S; Somaiah N; Choi H; Heeres B; Wang WL; van Boven H; Nederlof P; Benjamin R; van der Graaf W; Grunhagen D; Boonstra PA; Reyners AK; Gelderblom H; Steeghs N
    Eur J Cancer; 2017 May; 76():76-83. PubMed ID: 28284172
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of Imatinib in Patients with Platelet-Derived Growth Factor Receptor Alpha-Mutated Gastrointestinal Stromal Tumors.
    Yoo C; Ryu MH; Jo J; Park I; Ryoo BY; Kang YK
    Cancer Res Treat; 2016 Apr; 48(2):546-52. PubMed ID: 26130666
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Switch Control Inhibition of KIT and PDGFRA in Patients With Advanced Gastrointestinal Stromal Tumor: A Phase I Study of Ripretinib.
    Janku F; Abdul Razak AR; Chi P; Heinrich MC; von Mehren M; Jones RL; Ganjoo K; Trent J; Gelderblom H; Somaiah N; Hu S; Rosen O; Su Y; Ruiz-Soto R; Gordon M; George S
    J Clin Oncol; 2020 Oct; 38(28):3294-3303. PubMed ID: 32804590
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Benefit of Avapritinib in KIT-Mutant Gastrointestinal Stromal Tumors: A Post Hoc Analysis of the Phase I NAVIGATOR and Phase I/II CS3007-001 Studies.
    Heinrich MC; Zhang X; Jones RL; George S; Serrano C; Deng Y; Bauer S; Cai S; Wu X; Zhou Y; Tao K; Zheng Z; Zhang J; Cui Y; Cao H; Wang M; Hu J; Yang J; Li J; Shen L
    Clin Cancer Res; 2024 Feb; 30(4):719-728. PubMed ID: 38032349
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.